Company Information

  

Address: 80 W. LANCASTER AVENUE
SUITE 300 
City: DEVON 
State: PA 
Zip Code: 19333 
Telephone: 484-581-7505 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Unless the context indicates otherwise, the terms "Zynerba," "Zynerba Pharmaceuticals," "we," "us," "our," "our company" and "our business" refer to Zynerba Pharmaceuticals, Inc. Company Overview We are a clinical stage specialty pharmaceutical company dedicated to developing and commercializing innovative transdermal synthetic cannabinoid treatments for patients with high unmet needs. We are evaluating two patent protected product candidates, ZYN002 and ZYN001, in five indications. We are studying ZYN002 in adult patients with refractory epileptic focal seizures (formerly known as complex partial seizures) and osteoarthritis, or OA, and in pediatric patients with fragile X syndrome, or FXS. We intend to study ZYN001 in patients with fibromyalgia and peripheral neuropathic pain.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
09/2017-2.59NAN/E
06/2017-2.63NAN/E
03/2017-2.69NAN/E
12/2016-2.58NAN/E
09/2016-2.31NAN/E
06/2016-1.86NAN/E
03/2016-2.28NAN/E
12/2015-2.82NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.31Total Liab/Total Assets0.19
Net Inc/Total Assets-0.64Total Liab/Inv Cap0.24
Net Inc/Inv Cap-0.79Total Liab/Comm Equity0.09
Pretax Inc/Net Sales-3229.80Interest Coverage RatioNA
Net Inc/Net Sales-3226.00Curr Debt/EquityNA
Cash Flow/Net Sales-2819.06LTD/EquityNA
SG&A/NetSales886.93Total Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables Turnover0.00Quick Ratio5.23
Inventory TurnoverNACurrent Ratio5.23
Inventory Day SalesNANet Rec/Curr Assets0.10
Net Sales/Work Cap0.00Inv/Curr AssetsNA
Net Sales/PP&E0.05  

Income Statement (Millions)

  9/30/2017 6/30/2017 3/31/2017 12/31/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.00
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 2.80 2.63 2.21 1.78
Operating Income -8.55 -8.37 -7.70 -6.68
Interest Exp NA NA NA NA
Pretax Income -8.31 -8.32 -7.26 -6.90
Other Income 0.24 0.04 0.44 -0.29
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -8.31 -8.32 -7.26 -6.90

Balance Sheet (Millions)

Assets 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Cash & Short Term Investments 66.25 70.18 77.49 30.97
Receivables - Total 3.62 3.97 3.87 3.61
Inventories - Total NA NA NA NA
Total Current Assets 72.88 76.46 83.36 36.41
Net Property, Plant & Equipment 0.19 0.18 0.20 0.14
Total Assets 73.07 79.09 84.70 36.55
Liabilities        
Accounts Payable 7.60 7.03 6.11 6.13
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 8.43 7.86 6.94 6.97
Long-Term Debt NA NA NA NA
Total Liabilities 8.43 7.86 6.94 6.97
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -69.86 -61.55 -53.23 -45.97
Treasury Stock NA NA NA NA
Total Stockholders' Equity 64.64 71.23 77.76 29.59
Total Liabilities and Stockholders' Equity 73.07 79.09 84.70 36.55

Cash Flow Summary (Millions)

Categories 9/30/2017 6/30/2017 3/31/2017 12/31/2016
Net Cash Provided by Operating Activities -3.81 -7.67 -7.65 -5.51
Net Cash Provided by Investing Activities -0.01 -0.01 -0.07 -0.02
Net Cash Provided by Financing Activities -0.11 0.37 54.25 4.71

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20130.94-0.64--
12/20140.81-5.67--
12/20150.28-12.55-2.82
12/20160.01-23.39-2.58
Growth Rates-80.27----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17803,61926.71




Report Date : 12/11/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.